The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1 - Wikidata - awgldk - TriplyDB

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

http://www.wikidata.org/entity/Q33725916

about

Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals.

P2860

Q41989387-7CD81328-E983-462A-A540-45EB7F8D8B15

P2860

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

http://www.wikidata.org/entity/Q33725916

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@ast

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@en

type

label

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@ast

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@en

prefLabel

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@ast

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@en

P1433

Q33725916-B983322C-C5AC-4421-812C-D8878308FD83

P1476

Q33725916-7AF0E72B-C54A-4170-A6DC-C37B26FD4ACD

P2093

Q33725916-68454A59-73C6-47B1-8D53-DB235B1691F3

Q33725916-D11C86BD-70C2-482E-803C-1AAB7BF1C67D

Q33725916-DDA995C3-E995-4300-AB48-296A15F10E9D

Q33725916-E3F7C202-0051-44C7-908D-1B8CD706D0C7

P2860

Q33725916-076D8466-7C51-49F3-B341-2A8B15AAB59C

Q33725916-0EAEEC74-7A3D-4319-82A0-C84AFD63AC4B

Q33725916-0FC441EF-1AF8-4DC8-9218-385C9A2284DF

Q33725916-17714E43-65E5-4B38-BDB8-7701AECDF8B6

Q33725916-1F1A986B-A81D-4D6B-A5C9-D65C8648E2C8

Q33725916-23294265-7C47-4154-8A65-FE170C30DFFB

Q33725916-2612F0F1-BCF5-4647-BBE9-6E283195A8BE

Q33725916-2678541D-E8D9-4E2C-9B11-9ABF22A1927B

Q33725916-268C769E-32BB-40C6-8831-43C5DD1311B0

Q33725916-276E4C87-A879-4FFD-AF5F-08F5645CEC68

P2888

Q33725916-AA522F1E-4BF5-4A27-AB33-E29FE9AC45D9

P304

Q33725916-22FBED96-A349-43A0-9E40-1683D2F05819

P31

Q33725916-C7D6A55A-8054-498A-BB33-2DAFCADCB577

P356

Q33725916-E893F6DC-AD1C-498C-A913-C20B9ABB3520

P407

Q33725916-CEA9323B-645D-4593-AF86-F6C05D2F3DB0

P433

Q33725916-D1676FDD-EF29-4D95-94F9-375F3D3A993A

P478

Q33725916-4EED6A38-1E7F-440D-B34E-B92081A8465F

P50

Q33725916-122F0D4B-A2B1-4458-893D-08C36A196B2C

Q33725916-3FFB8431-79A0-43E1-9339-4713B7B54537

Q33725916-4D434B22-A972-4777-9C1D-E778EE7693EC

Q33725916-F0D3813C-94F1-4E9C-A22A-6776E104F639

P577

Q33725916-B5C891D8-634C-472E-A66B-6A2FEC63B12A

P6179

Q33725916-02BC79FA-4326-4178-8E44-307402262A38

P698

Q33725916-74CEAD09-0678-400B-BB12-CD101D7F3EFC

P921

Q33725916-90E8A314-49F5-4C60-9E2B-ECEDA4EB9805

P932

Q33725916-79BE90E6-B03A-4604-845A-1B2F94FAF59B

P356

S41598-017-02634-Y

P1433

Scientific Reports

P1476

The CCR5-antagonist Maraviroc ...... h the PKC-agonist Bryostatin-1

@en

P2093

Carolina Gutiérrez

http://www.w3.org/2001/XMLSchema#string

Laura Jiménez-Tormo

http://www.w3.org/2001/XMLSchema#string

Nadia Madrid-Elena

http://www.w3.org/2001/XMLSchema#string

Santiago Moreno

http://www.w3.org/2001/XMLSchema#string

P2860

Absolute dependence on kappa B responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 T lymphocytes

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

Maraviroc: a review of its use in HIV infection and beyond

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

Maraviroc: pharmacokinetics and drug interactions

Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression

Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected

P2888

s41598-017-02634-y

P304

2385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-02634-Y

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Mayte T. Coiras

María Rosa López-Huertas

Sara Rodríguez-Mora

P577

2017-05-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085537770

http://www.w3.org/2001/XMLSchema#string

P698

28539614

http://www.w3.org/2001/XMLSchema#string

P921

P932

5443841

http://www.w3.org/2001/XMLSchema#string